FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4229060183> ?p ?o ?g. }

• W4229060183 endingPage "987.e2" @default.
• W4229060183 startingPage "978" @default.
• W4229060183 abstract "Direct oral anticoagulants (DOACs) may simplify management of Budd-Chiari syndrome (BCS). Here, we report our experience with off-label use of DOACs for anticoagulation in BCS.The safety of DOAC vs vitamin K antagonist treatment as well as associated clinical outcomes were retrospectively assessed in 47 BCS patients treated at 6 Austrian centers.Mean age at study inclusion was 37.9 ± 14.0 years and mean Model for End-Stage Liver Disease was 13.1 ± 5.1. Overall, 63.8% (n = 30) of patients had decompensated liver disease, and 87.2% (n = 41) showed clinical signs of portal hypertension. During a median follow-up of 82.5 (interquartile range, 43.1-121.8) months, 43 (91.5%) patients received anticoagulation alone or following interventional treatment, including 22 (46.8%) patients treated with DOACs (edoxaban: 10, apixaban: 4, rivaroxaban: 3, dabigatran: 3, more than one DOAC sequentially: 2) for a median of 24.4 (interquartile range, 5.7-35.1) months. While 72.7% (n = 16 of 22) of patients were switched from low-molecular-weight heparin (n = 12) or vitamin K antagonist (n = 4) to DOAC after disease stabilization or improvement, 27.3% (n = 6 of 22) of BCS patients were initially treated with DOAC. Complete response (European Association for the Study of the Liver criteria) was achieved or maintained in 14 (63.6%) of 22 patients, with ongoing response in 2 patients, while disease progressed in 6 patients (including 2 patients with hepatocellular carcinoma). Four major spontaneous bleedings (18.2%; incidence rate 8.8 per 100 patient-years; n = 2 upper gastrointestinal bleeding, n = 1 lower gastrointestinal bleeding, n = 1 hepatocellular carcinoma rupture), 7 minor bleedings, and 1 major procedure-related bleeding (4.5%; 2.2 per 100 patient-years) occurred during DOAC therapy. Overall transplant-free survival was 91.6% at 5 years.DOACs seem to be effective and safe for long-term anticoagulation in patients with BCS, but confirmation by larger prospective studies is needed." @default.
• W4229060183 created "2022-05-08" @default.
• W4229060183 creator A5000713998 @default.
• W4229060183 creator A5001144757 @default.
• W4229060183 creator A5007306984 @default.
• W4229060183 creator A5011613300 @default.
• W4229060183 creator A5020745145 @default.
• W4229060183 creator A5024485263 @default.
• W4229060183 creator A5040216528 @default.
• W4229060183 creator A5046244856 @default.
• W4229060183 creator A5047158945 @default.
• W4229060183 creator A5047963027 @default.
• W4229060183 creator A5048534007 @default.
• W4229060183 creator A5057597698 @default.
• W4229060183 creator A5060597741 @default.
• W4229060183 creator A5061474122 @default.
• W4229060183 creator A5067605507 @default.
• W4229060183 creator A5087316703 @default.
• W4229060183 creator A5088680222 @default.
• W4229060183 creator A5090751499 @default.
• W4229060183 date "2023-04-01" @default.
• W4229060183 modified "2023-10-13" @default.
• W4229060183 title "Outcome of Budd-Chiari Syndrome Patients Treated With Direct Oral Anticoagulants: An Austrian Multicenter Study" @default.
• W4229060183 cites W1971211622 @default.
• W4229060183 cites W1978840084 @default.
• W4229060183 cites W1994471233 @default.
• W4229060183 cites W1996837393 @default.
• W4229060183 cites W2025528214 @default.
• W4229060183 cites W2030293340 @default.
• W4229060183 cites W2050437797 @default.
• W4229060183 cites W2076651612 @default.
• W4229060183 cites W2079377322 @default.
• W4229060183 cites W2109906869 @default.
• W4229060183 cites W2115787552 @default.
• W4229060183 cites W2128637211 @default.
• W4229060183 cites W2139785591 @default.
• W4229060183 cites W2144990123 @default.
• W4229060183 cites W2153802696 @default.
• W4229060183 cites W2533474819 @default.
• W4229060183 cites W2545803831 @default.
• W4229060183 cites W2808876361 @default.
• W4229060183 cites W2898287068 @default.
• W4229060183 cites W2904330433 @default.
• W4229060183 cites W2908890541 @default.
• W4229060183 cites W2914381505 @default.
• W4229060183 cites W2950337259 @default.
• W4229060183 cites W2954443719 @default.
• W4229060183 cites W2972057389 @default.
• W4229060183 cites W2989714602 @default.
• W4229060183 cites W3004944841 @default.
• W4229060183 cites W3010459779 @default.
• W4229060183 cites W3016703611 @default.
• W4229060183 cites W3030222297 @default.
• W4229060183 cites W3048061620 @default.
• W4229060183 cites W3103618496 @default.
• W4229060183 cites W3174226404 @default.
• W4229060183 cites W3180918825 @default.
• W4229060183 doi "https://doi.org/10.1016/j.cgh.2022.04.024" @default.
• W4229060183 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35533994" @default.
• W4229060183 hasPublicationYear "2023" @default.
• W4229060183 type Work @default.
• W4229060183 citedByCount "8" @default.
• W4229060183 countsByYear W42290601832022 @default.
• W4229060183 countsByYear W42290601832023 @default.
• W4229060183 crossrefType "journal-article" @default.
• W4229060183 hasAuthorship W4229060183A5000713998 @default.
• W4229060183 hasAuthorship W4229060183A5001144757 @default.
• W4229060183 hasAuthorship W4229060183A5007306984 @default.
• W4229060183 hasAuthorship W4229060183A5011613300 @default.
• W4229060183 hasAuthorship W4229060183A5020745145 @default.
• W4229060183 hasAuthorship W4229060183A5024485263 @default.
• W4229060183 hasAuthorship W4229060183A5040216528 @default.
• W4229060183 hasAuthorship W4229060183A5046244856 @default.
• W4229060183 hasAuthorship W4229060183A5047158945 @default.
• W4229060183 hasAuthorship W4229060183A5047963027 @default.
• W4229060183 hasAuthorship W4229060183A5048534007 @default.
• W4229060183 hasAuthorship W4229060183A5057597698 @default.
• W4229060183 hasAuthorship W4229060183A5060597741 @default.
• W4229060183 hasAuthorship W4229060183A5061474122 @default.
• W4229060183 hasAuthorship W4229060183A5067605507 @default.
• W4229060183 hasAuthorship W4229060183A5087316703 @default.
• W4229060183 hasAuthorship W4229060183A5088680222 @default.
• W4229060183 hasAuthorship W4229060183A5090751499 @default.
• W4229060183 hasBestOaLocation W42290601831 @default.
• W4229060183 hasConcept C119060515 @default.
• W4229060183 hasConcept C126322002 @default.
• W4229060183 hasConcept C141071460 @default.
• W4229060183 hasConcept C2776208725 @default.
• W4229060183 hasConcept C2776301958 @default.
• W4229060183 hasConcept C2776704044 @default.
• W4229060183 hasConcept C2777075537 @default.
• W4229060183 hasConcept C2778661090 @default.
• W4229060183 hasConcept C2778810321 @default.
• W4229060183 hasConcept C2779161974 @default.
• W4229060183 hasConcept C2780290652 @default.
• W4229060183 hasConcept C2780638905 @default.
• W4229060183 hasConcept C2910216633 @default.
• W4229060183 hasConcept C71924100 @default.

• next